Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Efficacy of the Therapy With BRAINMAX® Using fMRI for the Treatment of Patients With Asthenia After COVID-19
- Conditions
- Functional MRICognitive ImpairmentAstheniaCOVID-19
- Interventions
- Other: Structural and functional MRIDrug: Ethyl methyl hydroxypyridine succinate + MeldoniumDrug: Placebo
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Promomed, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT05939622
- Locations
- 🇷🇺
Federal State Budgetary Research Institution "Research Centre of Neurology", Moscow, Russian Federation
Efficacy and Safety of Sibutramin-containing Drugs in Patient With Alimentary Obesity
- Conditions
- Obesity
- Interventions
- Drug: metformin+sibutramine
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Promomed, LLC
- Target Recruit Count
- 240
- Registration Number
- NCT05821543
- Locations
- 🇷🇺
Ivanovo Clinical Hospital named after Kuvaev, Ivanovo, Russian Federation
🇷🇺Kirov State Medical University, Kirov, Russian Federation
🇷🇺Pirogov Russian National Research Medical University, Moscow, Russian Federation
Study for Efficacy and Safety Assessment of the Drug RADAMIN®VIRO for COVID-19 Postexposure Prophylaxis
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Promomed, LLC
- Target Recruit Count
- 800
- Registration Number
- NCT05722691
- Locations
- 🇷🇺
Regional Budgetary Healthcare Institution Ivanovo Clinical Hospital, Ivanovo, Russian Federation
🇷🇺Federal State Budgetary Educational Institution of Higher Education Kirov State Medical University of Ministry of Health of the Russian Federation, Kirov, Russian Federation
🇷🇺State Budgetary Healthcare Institution of Moscow Municipal Clinical Hospital Named after S. I. Spasokukotsky of Moscow Healthcare Department, Moscow, Russian Federation
Safety and Efficacy of the Therapy With BRAINMAX® for the Treatment of Patients With Asthenia After COVID-19
- Conditions
- AstheniaCOVID-19
- Interventions
- Drug: Ethyl methyl hydroxypyridine succinate + MeldoniumDrug: Placebo
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Promomed, LLC
- Target Recruit Count
- 160
- Registration Number
- NCT05689827
- Locations
- 🇷🇺
Federal State Budgetary Research Institution "Research Centre of Neurology", Moscow, Russian Federation
🇷🇺OsteoVita LLC, Saint Petersburg, Russian Federation
🇷🇺Saint Petersburg State Budgetary Healthcare Institution "Municipal Hospital No. 40 of Kurortny District", Sestroretsk, Russian Federation
Efficacy and Safety of Ambervin® and Standard Therapy in Hospitalized Patients With COVID-19
- Conditions
- COVID-19
- Interventions
- Drug: Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate inhaledDrug: Standard of careDrug: Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate intramuscularly
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Promomed, LLC
- Target Recruit Count
- 313
- Registration Number
- NCT05656495
- Locations
- 🇷🇺
Budgetary institution of the Chuvash Republic "Emergency Hospital", Cheboksary, Russian Federation
🇷🇺City clinical Hospital №24, Moscow, Russian Federation
🇷🇺Infectious Clinical Hospital No.1, Moscow, Russian Federation
- Prev
- 1
- 2
- Next